16.12.2012 Views

Therapies for Children With Autism Spectrum Disorders

Therapies for Children With Autism Spectrum Disorders

Therapies for Children With Autism Spectrum Disorders

SHOW MORE
SHOW LESS

Create successful ePaper yourself

Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.

Evidence Table. <strong>Therapies</strong> <strong>for</strong> children with ASD<br />

Study<br />

Inclusion/Exclusion<br />

Description Intervention<br />

Criteria/Population<br />

2004<br />

Rivastigmine tartarate ASD or PDD-NOS per<br />

Country:<br />

DSM-IV<br />

US<br />

At BL, 0.2 ml (0.4 mg) of Exclusion criteria:<br />

rivastigmine tartarate See inclusion criteria<br />

Practice given twice daily in a Age, mean/yrs (range):<br />

setting: Specialty liquid suspension 6.91 (2.85-12)<br />

treatment center (2mg.ml). If any adverse Mental age: NR<br />

event, dosage was Gender:<br />

halved or discontinued. M, n (%): 24 (75)<br />

If no improvement after 2 F, n (%): 8 (25)<br />

wks of starting on the<br />

medicaton, dosage was Race/ethnicity:<br />

doubled to 0.4 ml (0.8mg) NR<br />

twice daily<br />

SES:<br />

Maternal education: NR<br />

Intervention<br />

setting: Clinic<br />

Enrollment<br />

period:<br />

Month : NR<br />

Funding:<br />

NR<br />

Author industry<br />

relationship<br />

disclosures:<br />

NR<br />

Design:<br />

Prospective case<br />

series<br />

Maximum daily dose was<br />

0.4 ml (0.8mg) twice daily<br />

Assessments:<br />

Expressive One Word<br />

Vocabulary Test,<br />

Childhood <strong>Autism</strong> Rating<br />

Scale administered by<br />

study coordinator at<br />

baseline, 6wks and 12<br />

wks. Conners’ Parent<br />

Rating Scale completed<br />

by parents at baseline,<br />

6wks, 12 wks.<br />

Groups:<br />

Other characteristics, n<br />

G1: Rivastigmine (%):<br />

tartarate<br />

Previous diagnosis of<br />

Co-interventions held nocturnal epilepti<strong>for</strong>m EEG<br />

stable during treatment: abnormalities: 13 (40.6)<br />

NR<br />

Frequency of contact<br />

during study: Testing at<br />

Baseline, 6 weeks, 12<br />

weeks. Nurses contacted<br />

parents weekly to check<br />

<strong>for</strong> any concerns.<br />

Concomitant therapies,<br />

n:<br />

Anticonvulsants: 21<br />

CNS stimulants: 8<br />

Adrenergic blockers: 4<br />

Antipsychotics: 2<br />

Antidepressants: 1<br />

Corticosteroids: 1<br />

N at enrollment:<br />

G1: 32<br />

Household income: NR<br />

Diagnostic approach:<br />

In Study/Referral<br />

Diagnostic tool/method:<br />

DSM-IV<br />

Diagnostic category, n<br />

(%):<br />

<strong>Autism</strong>: 11 (34.4)<br />

PDD-NOS : 21 (65.6)<br />

C-334<br />

Baseline<br />

Measures Outcomes<br />

34 ± 6.36<br />

weeks:<br />

Overall ratings:<br />

CARS, mean ±<br />

SD: 30.84 ± 8.71<br />

P = 0.001<br />

Communication/<br />

language:<br />

Expressive one-word<br />

Picture vocabulary<br />

test, mean ± SD:<br />

34.91 ± 33.61<br />

Receptive One-word<br />

Picture Vocabulary<br />

test, mean ± SD:<br />

37.78 ± 29.70<br />

Problem behavior:<br />

Conner’s parent<br />

rating scale, mean ±<br />

SD: 34.5 ± 12.30<br />

Communication/<br />

language:<br />

Expressive oneword<br />

Picture<br />

vocabulary test ,<br />

mean ± SD:<br />

41.44 ± 36.74<br />

P = 0.001<br />

Receptive Oneword<br />

Picture<br />

Vocabulary test,<br />

mean ± SD:<br />

39.53 ± 32.47<br />

P = NS<br />

Problem<br />

behavior:<br />

Conner’s parent<br />

rating scale,<br />

mean ± SD: 28.28<br />

± 13.53<br />

P = 0.005<br />

Harms:<br />

NR<br />

Modifiers:<br />

NR

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!